Welcome to
Madrigal Medical Affairs
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction steatohepatitis (MASH/NASH).
Welcome to Madrigal Medical Affairs
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction steatohepatitis (MASH/NASH).
Metabolic Dysfunction Steatohepatitis (MASH/NASH)
Metabolic Dysfunction Steatohepatitis (MASH/NASH)
Metabolic Dysfunction Steatohepatitis (MASH/NASH)
A Chronic Liver Disease
MASH/NASH* is a leading cause of liver-related mortality and an increasing burden on global healthcare systems.
*The nomenclature is transitioning from NASH (nonalcoholic steatohepatitis) to MASH (metabolic dysfunction steatohepatitis) and NAFLD (nonalcoholic fatty liver disease) to MASLD (metabolic associated liver disease)
A Chronic Liver Disease
MASH/NASH* is a leading cause of liver-related mortality and an increasing burden on global healthcare systems.
*The nomenclature is transitioning from NASH (nonalcoholic steatohepatitis) to MASH (metabolic dysfunction steatohepatitis) and NAFLD (nonalcoholic fatty liver disease) to MASLD (metabolic associated liver disease)
The Role of Thyroid Hormone Receptor β (THR-β) in MASH/NASH
In MASH/NASH, reduced signaling via THR-β exacerbates hepatic mitochondrial dysfunction, inflammation, and fibrosis.
The Role of Thyroid Hormone Receptor β (THR-β) in NASH
In MASH/NASH, reduced signaling via THR-β exacerbates hepatic mitochondrial dysfunction, inflammation, and fibrosis.
Melody.education
Learn more about MASH/NASH with educational programs and podcasts (non-CME) presented by leading MASH/NASH experts. Be sure to become a member to receive regular updates on new content and test your knowledge with Clinician Challenge questions.
Melody.education
Learn more about MASH/NASH with educational programs and podcasts (non-CME) presented by leading MASH/NASH experts. Be sure to become a member to receive regular updates on new content and test your knowledge with Clinician Challenge questions.
Learn More About MASH/NASH
Our Research
Our Research
Our Research
MAESTRO Clinical Development Program
Our clinical development program focuses on a thyroid hormone receptor-β (THR-β) agonist being studied for the treatment of MASH/NASH.
MAESTRO Clinical Development Program
Our clinical development program focuses on a thyroid hormone receptor-β (THR-β) agonist being studied for the treatment of MASH/NASH.
Publications
View key resmetirom and clinical publications along with recent congress presentations.
Publications
View key resmetirom and clinical publications along with recent congress presentations.
Request Medical Information
Request Medical Information
Request Medical Information
Submit an Educational Grant Request
Submit an Educational Grant Request
Submit an Educational Grant Request
Investigator-Initiated Studies
Investigator-Initiated Studies
Investigator-Initiated Studies
Contact Us
Contact Us
Contact Us
Resmetirom is currently only approved in the United States.